Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.
暂无分享,去创建一个
Paul Zhang | A. Chalian | C. Koch | S. Evans | Paul J. L. Zhang | Cameron J Koch | Sydney M Evans | Ara A Chalian | Amy E Schrlau | Amy E. Schrlau
[1] S. Lahiri,et al. Intracellular PO2 of the carotid body. , 2000, Advances in experimental medicine and biology.
[2] G. Stevens,et al. Radiosensitization of mouse skin by oxygen and depletion of glutathione. , 1995, International journal of radiation oncology, biology, physics.
[3] H. Aro,et al. Irradiation‐Induced Hypoxia in Bones and Soft Tissues: An Experimental Study , 1986, Plastic and reconstructive surgery.
[4] C. Koch,et al. Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers. , 1993, Biochemical pharmacology.
[5] L. M. Cobb,et al. Microscopic distribution of misonidazole in mouse tissues. , 1989, British Journal of Cancer.
[6] M. Hauer-Jensen,et al. The radiotherapeutic injury--a complex 'wound'. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] J. Koziol,et al. Normal transcutaneous oxygen pressure in skin after radiation therapy for cancer , 1994, Cancer.
[8] S. Hahn,et al. Hypoxia in human intraperitoneal and extremity sarcomas. , 2001, International journal of radiation oncology, biology, physics.
[9] D. Fraker,et al. EF5 binding and clinical outcome in human soft tissue sarcomas. , 2006, International journal of radiation oncology, biology, physics.
[10] C. Koch,et al. Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation , 2001, American journal of clinical oncology.
[11] Dao-Yi Yu,et al. Retinal degeneration and local oxygen metabolism. , 2005, Experimental eye research.
[12] J. Kristl,et al. Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[13] L. M. Cobb,et al. Autoradiographic study of tritium-labeled misonidazole in the mouse. , 1989, International journal of radiation oncology, biology, physics.
[14] T. K. Hunt,et al. Oxygen: At the Foundation of Wound Healing—Introduction , 2004, World Journal of Surgery.
[15] P. Declerck,et al. In vitro reductive activation of nitroimidazoles. , 1986, Biochemical pharmacology.
[16] S. Hahn,et al. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ]. , 2000, Cancer research.
[17] Peter T. Nelson,et al. Comparative Measurements of Hypoxia in Human Brain Tumors Using Needle Electrodes and EF5 Binding , 2004, Cancer Research.
[18] C. Koch,et al. Chondrocytes in the endochondral growth cartilage are not hypoxic. , 1997, The American journal of physiology.
[19] Till Acker,et al. Cellular oxygen sensing need in CNS function: physiological and pathological implications , 2004, Journal of Experimental Biology.
[20] Peter T. Nelson,et al. Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors , 2004, Clinical Cancer Research.
[21] C. Koch,et al. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. , 1996, Cancer research.
[22] S M Evans,et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. , 2000, Cancer research.
[23] T. Utsunomiya,et al. The difference in chemosensitivity to antineoplastic agents of human hepatocellular carcinoma cells under normo-oxygenated or hypoxic conditions. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[24] C. Koch. The Reduction Activation of Nitroimidazoles; Modification by Oxygen and other Redox-Active Molecules in Cellular Systems , 1990 .
[25] Thomas A. Mustoe, MD, FACS,et al. Oxygen in Wound Healing—More than a Nutrient , 2004, World Journal of Surgery.
[26] G. Adams. Hypoxia‐mediated druGS FOR RADIATION AND CHEMOTHERAPY , 1981 .
[27] L. H. Gray,et al. The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.
[28] C. Koch,et al. Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro. , 1987, Cancer research.
[29] María Angeles Peinado,et al. The role of free radicals in cerebral hypoxia and ischemia. , 2005, Free radical biology & medicine.
[30] C. Koch,et al. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles , 2001, Cancer Chemotherapy and Pharmacology.
[31] M. Dewhirst,et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. , 2004, Cancer cell.
[32] G. Wilson,et al. Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys. , 1992, International journal of radiation oncology, biology, physics.
[33] L. Wiebe,et al. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. , 1992, British Journal of Cancer.
[34] C. Koch,et al. Permanent Anatomic Closure of the Ductus Arteriosus in Newborn Baboons: The Roles of Postnatal Constriction, Hypoxia, and Gestation , 1999, Pediatric Research.
[35] J. Brown,et al. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. , 1991, International journal of radiation oncology, biology, physics.
[36] L. M. Cobb,et al. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues. , 1990, British Journal of Cancer.
[37] J. Pouysségur,et al. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. , 2001, Trends in cell biology.
[38] L. M. Cobb,et al. Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse. , 1990, International journal of radiation oncology, biology, physics.
[39] F. Stewart,et al. Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. , 1982, British Journal of Cancer.
[40] C. Koch,et al. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. , 2002, Methods in enzymology.
[41] E. Fuchs,et al. Defining the Epithelial Stem Cell Niche in Skin , 2004, Science.
[42] L. M. Cobb,et al. NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole. , 1990, British Journal of Cancer.
[43] C. Koch,et al. Imaging hypoxia and blood flow in normal tissues. , 1997, Advances in experimental medicine and biology.
[44] D. Ferriero,et al. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia–ischemia , 1999, Neuroscience.
[45] Abels Ri. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. , 1992 .
[46] C. Koch,et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. , 1996, The Journal of pharmacology and experimental therapeutics.
[47] Amato J Giaccia,et al. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. , 2005, Cancer cell.
[48] C. Koch,et al. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. , 2002, Cancer research.
[49] C. Koch,et al. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.